{"analyses":[{"ciLowerLimit":"0.665","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.959","estimateComment":"The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.","groupDescription":"D + EP vs EP. HR \\<1 favors D + EP to be associated with a longer PFS than EP.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0157","pValueComment":"Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.","paramType":"Hazard Ratio (HR)","paramValue":"0.80","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.696","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.005","estimateComment":"The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.","groupDescription":"D + T + EP vs EP. HR \\<1 favors D + T + EP to be associated with a longer PFS than EP.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0568","pValueComment":"Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.","paramType":"Hazard Ratio (HR)","paramValue":"0.84","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.857","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.235","estimateComment":"The HR and CIs were calculated using a stratified Cox proportional hazards model, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and ties handled by Efron approach.","groupDescription":"D + T + EP vs D + EP. HR \\<1 favors D + T + EP to be associated with a longer PFS than D + EP.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7540","pValueComment":"Analysis was performed using the stratified log-rank test, adjusting for planned platinum therapy in Cycle 1 (carboplatin or cisplatin), and using the rank tests of association approach.","paramType":"Hazard Ratio (HR)","paramValue":"1.03","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"5.9","value":"4.9"},{"groupId":"OG001","lowerLimit":"4.7","upperLimit":"6.2","value":"5.1"},{"groupId":"OG002","lowerLimit":"4.8","upperLimit":"6.2","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"268"},{"groupId":"OG002","value":"269"}],"units":"Participants"}],"description":"PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \\[RECIST 1.1\\] using Investigator assessments) was defined as time from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Progression (ie, PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir) and an absolute increase of ≥5 millimeters (mm) for the sum from nadir. For evaluation of non-target lesions (NTLs), PD was defined as unequivocal progression of existing NTLs. Median PFS was calculated using the Kaplan-Meier technique.","dispersionType":"95% Confidence Interval","groups":[{"description":"During Chemotherapy:\n\nPatients received durvalumab (D) 1500 mg in combination with tremelimumab (T) 75 mg IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9). For chemotherapy (EP), patients received etoposide (80-100 mg/m\\^2) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 mg/m\\^2) IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9).\n\nPost-Chemotherapy:\n\nPatients then continued to receive durvalumab 1500 mg IV infusion Q4W from Week 12 until PD, unless there was unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met. Patients also received an additional dose of tremelimumab 75 mg IV infusion post-chemotherapy (in combination with durvalumab) at Week 16 if they completed all 4 doses of durvalumab + tremelimumab during chemotherapy.","id":"OG000","title":"Global Cohort: D + T + EP"},{"description":"During Chemotherapy:\n\nPatients received durvalumab (D) 1500 mg IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9). For chemotherapy (EP), patients received etoposide (80-100 mg/m\\^2) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 mg/m\\^2) IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9).\n\nPost-Chemotherapy:\n\nPatients then continued to receive durvalumab 1500 mg IV infusion Q4W from Week 12 until PD, unless there was unacceptable toxicity, withdrawal of consent, or another discontinuation criterion was met.","id":"OG001","title":"Global Cohort: D + EP"},{"description":"For chemotherapy (EP), patients received etoposide (80-100 mg/m\\^2) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 mg/m\\^2) IV infusion Q3W for 4 doses/cycles (Weeks 0, 3, 6 and 9). An additional 2 doses of EP (at Weeks 12 and 15) could be given at the investigators' discretion if clinically indicated.","id":"OG002","title":"Global Cohort: EP"}],"paramType":"MEDIAN","populationDescription":"The global FAS included all patients randomized prior to the end of global recruitment.","reportingStatus":"POSTED","timeFrame":"Tumour scans performed at baseline, Week 6, Week 12 then every 8 weeks relative to the date of randomization until RECIST 1.1-defined progression. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).","title":"Progression-Free Survival (PFS) in the Global Cohort","type":"SECONDARY","unitOfMeasure":"months"}